8:35 AM ET
8-K
Research Collaboration
Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B
Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.
- Value
- $1.88B
- Counterparty
- Gilead Sciences, Inc.